← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
26	AGTC 26 DELISTED Applied Genetic Technologies Corporation AGTC	95	+1	+1%	$102M
27	SIOX 27 DELISTED Sio Gene Therapies Inc. Common Stock SIOX	95	+14	+17%	$1.43B
28	28 Lineage Cell Therapeutics LCTX $232M	80	+6	+8%	$153M
29	29 Rocket Pharmaceuticals RCKT $243M	78	+12	+18%	$207M
30	30 DELISTED Adverum Biotechnologies ADVM	76	-1	-1%	$62.7M
31	31 Atara Biotherapeutics ATRA $96M	76	+2	+3%	$479M
32	32 Editas Medicine EDIT $349M	75	+7	+10%	$301M
33	ATHX 33 DELISTED Athersys, Inc. Common Stock ATHX	73	-5	-6%	$30.6M
34	34 Regenxbio RGNX $454M	71	+2	+3%	$237M
35	BLCM 35 DELISTED Bellicum Pharmaceuticals, Inc. BLCM	70	+3	+4%	$371M
36	36 Invesco Biotechnology & Genome ETF PBE $421M	68	-5	-7%	$56.9M
37	37 Intellia Therapeutics NTLA $1.6B	65	+3	+5%	$243M
38	38 Veracyte VCYT $3.5B	55	-3	-5%	$119M
39	39 Voyager Therapeutics VYGR $124M	53	+5	+10%	$128M
40	40 Fortress Biotech FBIO $63.4M	51	-1	-2%	$21.2M
41	NVTA 41 DELISTED Invitae Corporation NVTA	51	+2	+4%	$186M
42	42 uniQure QURE $1.45B	49	-10	-17%	$54.1M
43	43 Arbutus Biopharma ABUS $830M	48	-3	-6%	$115M
44	44 Lakefront Biotherapeutics American Depositary Shares LKFT $1.93B	48	+10	+26%	$628M
45	45 DELISTED NeuBase Therapeutics, Inc. Common Stock NBSE	47	-4	-8%	$9.3M
46	ADAP 46 DELISTED Adaptimmune Therapeutics ADAP	46	-1	-2%	$218M
47	47 Neurogene NGNE $444M	46	+12	+35%	$306M
48	48 Wave Life Sciences WVE $609M	46	+7	+18%	$457M
49	49 Vericel Corp VCEL $2.06B	45	-7	-13%	$21.8M
50	50 Fate Therapeutics FATE $232M	40	+1	+3%	$60.8M